# **SAFETY DATA SHEETS**

# This SDS packet was issued with item:

078949958

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078949944 078949959 078949960



According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 04.24.2024 Page 1 of 10

Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

#### **SECTION 1: Identification**

#### **Product Identifier**

Product Name: Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg,

160mg | 4s (RX)

**Synonyms:** (2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)

quinuclidin-3-amine citrate monohydrate

**Product code:** 78949944, 78949958, 78949959, 78949960

#### **Recommended Use of the Product and Restriction on Use**

**Relevant Identified Uses:** Functions as Neurokinin (NK1) receptor antagonist that blocks the pharmacological action of substance P in the central nervous system (CNS).

**Uses Advised Against:** Any use other than recommended above.

**Reasons Why Uses Advised Against:** Not determined or not applicable.

#### **Manufacturer or Supplier Details**

# Supplier:

#### **United States**

Aspen Veterinary Resources, LTD. 3155 W. Heartland Drive Liberty, MO 64068 1-800-792-1238

# **Emergency Telephone Number:**

#### **United States**

CHEMTREC

Within USA and Canada: 1-800-424-9300 (24 hours)
Outside USA and Canada: +1-703-527-3887 (24 hours)

#### SECTION 2: Hazard(s) Identification

## **GHS Classification:**

Serious eye damage, category 1 Specific target organ toxicity - repeated exposure, category 2

# **Label elements**

# **Hazard Pictograms:**





Signal Word: Danger

#### **Hazard statements:**

H318 Causes serious eye damage

H373 May cause damage to organs (lungs and liver) through prolonged or repeated oral exposure

**Precautionary Statements:** 

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 04.24.2024 Page 2 of 10

#### Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

P280 Wear protective gloves, protective clothing, eye protection and face protection

P260 Do not breathe dust

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing

P310 Immediately call a doctor

P314 Get medical advice and attention if you feel unwell

P501 Dispose of contents and container in accordance with federal, state and local regulations

Hazards Not Otherwise Classified: None

# **SECTION 3: Composition/Information on Ingredients**

Identification	Name	Weight %
CAS Number: 9004-34-6	Cellulose	50-60
CAS Number: 359875-09-5	Maropitant citrate monohydrate	20-30
CAS Number: 557-04-0	Magnesium distearate	<3

#### Additional Information:

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret in accordance with paragraph (i) of the OSHA Hazard Communication Standard (29 CFR §1910.1200).

# **SECTION 4: First Aid Measures**

# **Description of First Aid Measures**

#### **General Notes:**

Show this Safety Data Sheet to the doctor in attendance.

# **After Inhalation:**

If inhaled, remove person to fresh air and place in a position comfortable for breathing. Keep person at rest. If breathing is difficult, administer oxygen. If breathing has stopped, provide artificial respiration. If experiencing respiratory symptoms, seek medical advice/attention.

#### **After Skin Contact:**

Remove contaminated clothing and shoes. Rinse skin with copious amounts of water [shower] for several minutes. Launder contaminated clothing before reuse. If symptoms develop or persist, seek medical advice/attention.

# **After Eye Contact:**

Immediately rinse eyes with plenty of gently flowing lukewarm water for 15 minutes. Remove contact lenses if present and easy to do so. Protect unexposed eye. Seek immediate medical attention, preferably from an ophthalmologist.

#### **After Swallowing:**

If swallowed, DO NOT induce vomiting unless told to do so by a physician or poison control center. Rinse mouth with water. Never give anything by mouth to an unconscious person. If spontaneous vomiting occurs, place on the left side with head down to prevent aspiration of liquid into the lungs. If symptoms develop or persist, seek medical advice/attention.

# Most Important Symptoms and Effects, Both Acute and Delayed Acute Symptoms and Effects:

Eye contact may result in irritation, redness, pain, inflammation, itching, burning, tearing, corneal

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

**Initial Preparation Date: 04.24.2024** Page 3 of 10

#### Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

damage and loss of vision.

#### **Delayed Symptoms and Effects:**

May cause damage to organs (lungs and liver) through prolonged or repeated oral exposure.

#### **Immediate Medical Attention and Special Treatment**

#### **Specific Treatment:**

In case of eye contact, seek prompt medical attention while rinsing is continued.

#### **Notes for the Doctor:**

Provide general supportive measures and treat symptomatically. Keep victim under observation. Symptoms may be delayed.

## SECTION 5: Firefighting Measures

#### **Extinguishing Media**

#### **Suitable Extinguishing Media:**

Use extinguishing media appropriate to surrounding fire conditions.

#### **Unsuitable Extinguishing Media:**

Not determined or not applicable.

#### Specific Hazards During Fire-Fighting:

Thermal decomposition may produce irritating/toxic fumes/gases.

# **Special Protective Equipment for Firefighters:**

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full-face piece operated in positive pressure mode.

#### Special precautions:

Avoid contact with skin, eyes, hair and clothing. Do not breathe fumes/gas/mists/aerosols/vapors/dusts. Move containers from fire area if safe to do so. Use water spray/fog for cooling fire exposed containers. Avoid unnecessary run-off of extinguishing media which may cause pollution.

# **SECTION 6: Accidental Release Measures**

#### Personal Precautions, Protective Equipment, and Emergency Procedures:

Evacuate unnecessary personnel. Avoid dust formation. Ventilate area. Extinguish any sources of ignition. Wear recommended personal protective equipment (see Section 8). Avoid contact with skin, eyes and clothing. Do not breathe dust. Do not walk through spilled material. Wash thoroughly after handling.

#### **Environmental Precautions:**

Prevent further leakage or spillage if safe to do so. Prevent from reaching drains, sewers and waterways. Discharge into the environment must be avoided.

#### Methods and Material for Containment and Cleaning Up:

Large Spills: Stop the flow of material, if this is without risk. Ground/bond container and equipment. Sweep up or vacuum up spillage and collect in suitable container for disposal. Clean contaminated surface thoroughly.

Small Spills: Wipe up with a damp cloth and place in container for disposal. Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use.

Dispose of in accordance with all applicable regulations (see Section 13).

## **Reference to Other Sections:**

For personal protective equipment see Section 8. For disposal see Section 13.

#### **SECTION 7: Handling and Storage**

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 04.24.2024 Page 4 of 10

Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

#### **Precautions for Safe Handling:**

Use appropriate personal protective equipment (see Section 8). Use only with adequate ventilation. Do not handle, store or open near an open flame, sources of heat or sources of ignition. Protect material from direct sunlight. Avoid contact with eyes, skin and clothing. If tablets are crushed and/or broken, avoid breathing dust and contact with eyes. Avoid prolonged exposure. Do not eat, drink, smoke, or use personal products when handling chemical substances. Wash affected areas thoroughly after handling. Keep away from incompatible materials (See Section 10). Keep containers tightly closed when not in use.

# Conditions for Safe Storage, Including Any Incompatibilities:

Store in cool, dry, well-ventilated location out of direct sunlight. Keep away from food and beverages. Store away from heat, open flames and other sources of ignition. Store in original, tightly closed container. Store away from incompatible materials (See Section 10).

Keep away from heat, sparks and open flame.

#### **SECTION 8: Exposure Controls/Personal Protection**

Only those substances with limit values have been included below.

#### **Occupational Exposure Limit Values:**

Country (Legal Basis)	Substance	Identifier	Permissible concentration
ACGIH	Cellulose	9004-34-6	8-Hour TWA: 10 mg/m <sup>3</sup>
	Magnesium distearate	557-04-0	8-Hour TWA: 10 mg/m³ (Stearates, inhalable fraction)
	Magnesium distearate	557-04-0	8-Hour TWA: 3 mg/m³ (Stearates, respirable fraction)
NIOSH	Cellulose	9004-34-6	REL-TWA: 10 mg/m³ ([up to 10 hr] Total)
	Cellulose	9004-34-6	REL-TWA: 5 mg/m³ ([up to 10 hr] Respirable)
OSHA	Cellulose	9004-34-6	8-Hour TWA-PEL: 5 mg/m³ (Respirable fraction)
	Cellulose	9004-34-6	8-Hour TWA-PEL: 15 mg/m <sup>3</sup> (Total dust)
United States(California)	Cellulose	9004-34-6	8-Hour TWA-PEL: 10 mg/m³ (Particulate not otherwise regulated, total dust)
	Cellulose	9004-34-6	8-Hour TWA-PEL: 5 mg/m³ (Particulate not otherwise regulated, respirable fraction)
	Magnesium distearate	557-04-0	PEL: 10 mg/m <sup>3</sup>

#### **Biological Limit Values:**

No biological exposure limits noted for the ingredient(s).

#### **Information on Monitoring Procedures:**

Not determined or not applicable.

#### **Appropriate Engineering Controls:**

Emergency eye wash stations and safety showers should be available in the immediate vicinity of use or handling. Provide adequate ventilation to maintain the airborne concentrations of vapor, mists, and/or dusts below the applicable workplace exposure limits, while observing recognized national standards (or equivalent).

#### **Personal Protection Equipment**

#### **Eve and Face Protection:**

Use safety glasses with side shields or goggles. Use eye protection equipment that has been tested and

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 04.24.2024 Page 5 of 10

Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

approved by recognized national standards (or equivalent).

#### **Skin and Body Protection:**

Chemical resistant, impervious gloves approved by the appropriate standards. Gloves must be inspected prior to use. Avoid skin contact with used gloves. Appropriate techniques should be used to remove used gloves and contaminated clothing. Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Ensure that all personal protective equipment is approved by recognized national standards (or equivalent).

## **Respiratory Protection:**

No personal respiratory protective equipment normally required. In case of insufficient ventilation, wear suitable respiratory equipment. If engineering controls do not maintain airborne concentrations below the applicable workplace exposure limits, or to an acceptable level (if exposure limits have not been established), a respirator approved by recognized national standards (or equivalent) must be worn.

# **General Hygienic Measures:**

When handling chemical products, do not eat, drink or smoke. Wash hands after handling, before breaks, and at the end of the workday. Avoid contact with skin, eyes and clothing. Wash contaminated clothing before reuse. Perform routine housekeeping.

# **SECTION 9: Physical and Chemical Properties**

# **Information on Basic Physical and Chemical Properties**

Appearance	Peach, oval tablet
Odor	Not determined or not available.
Odor threshold	Not determined or not available.
рН	Not determined or not available.
Melting point/freezing point	Not determined or not available.
Initial boiling point/range	Not determined or not available.
Flash point (closed cup)	Not determined or not available.
Evaporation rate	Not determined or not available.
Flammability (solid, gas)	Not determined or not available.
Upper flammability/explosive limit	Not determined or not available.
Lower flammability/explosive limit	Not determined or not available.
Vapor pressure	Not determined or not available.
Vapor density	Not determined or not available.
Density	Not determined or not available.
Relative density	Not determined or not available.
Solubilities	Not determined or not available.
Partition coefficient (n-octanol/water)	Not determined or not available.
Auto/Self-ignition temperature	Not determined or not available.
Decomposition temperature	Not determined or not available.
Dynamic viscosity	Not determined or not available.
Kinematic viscosity	Not determined or not available.
Explosive properties	Not determined or not available.
Oxidizing properties	Not determined or not available.

#### **SECTION 10: Stability and Reactivity**

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

**Initial Preparation Date:** 04.24.2024 Page 6 of 10

#### Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

#### Reactivity:

Not reactive under recommended handling and storage conditions.

#### **Chemical Stability:**

Stable under recommended handling and storage conditions.

## Possibility of Hazardous Reactions:

Hazardous reactions are not anticipated under recommended conditions of handling and storage.

#### **Conditions to Avoid:**

Extreme heat, open flames, hot surfaces, sparks, ignition sources, sunlight, incompatible materials, generation and dispersal of dust

# **Incompatible Materials:**

Strong oxidizing agents, Fluorine

## **Hazardous Decomposition Products:**

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

# **SECTION 11: Toxicological Information**

#### **Acute Toxicity**

**Assessment:** Based on available data, the classification criteria are not met.

Product Data: No data available.

#### **Substance Data:**

Name	Route	Result
Cellulose	dermal	LD50 Rabbit: > 2000 mg/kg
	inhalation	LC50 Rat: > 5.8 mg/L (4 hr [dust])
	oral	LD50 Rat: > 5000 mg/kg

#### Skin Corrosion/Irritation

Assessment: Based on available data, the classification criteria are not met.

**Product Data:** No data available.

Substance Data: No data available.

# Serious Eye Damage/Irritation

#### **Assessment:**

Causes serious eye damage.

#### **Product Data:**

No data available.

# **Substance Data:**

Name	Result
Maropitant citrate monohydrate	Causes serious eye damage.

#### Respiratory or Skin Sensitization

Assessment: Based on available data, the classification criteria are not met.

**Product Data:** No data available.

Substance Data: No data available.

#### Carcinogenicity

Assessment: Based on available data, the classification criteria are not met.

Product Data: No data available. Substance Data: No data available.

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

**Initial Preparation Date:** 04.24.2024 Page 7 of 10

Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

#### International Agency for Research on Cancer (IARC):

Name	Classification
Cellulose	Group 1

#### **National Toxicology Program (NTP):**

Name	Classification
Cellulose	Known to be human carcinogens

**OSHA Carcinogens:** Not applicable

Germ Cell Mutagenicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product Data:** No data available.

Substance Data: No data available.

**Reproductive Toxicity** 

**Assessment:** Based on available data, the classification criteria are not met.

**Product Data:** No data available.

Substance Data: No data available.

**Specific Target Organ Toxicity (Single Exposure)** 

**Assessment:** Based on available data, the classification criteria are not met.

**Product Data:** No data available.

Substance Data: No data available.

Specific Target Organ Toxicity (Repeated Exposure)

**Assessment:** 

May cause damage to organs through prolonged or repeated exposure.

**Product Data:** No data available. **Substance Data:** 

Name	Result
Maropitant citrate	May cause damage to organs (lungs and liver) through prolonged or
monohydrate	repeated oral exposure.

#### Aspiration toxicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product Data:** No data available.

Substance Data: No data available.

Information on Likely Routes of Exposure:

Skin contact, ingestion, inhalation, eye contact.

Symptoms Related to the Physical, Chemical, and Toxicological Characteristics:

See section 4 of this SDS.

Other Information:

No data available.

# **SECTION 12: Ecological Information**

#### **Acute (Short-Term) Toxicity**

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

**Initial Preparation Date:** 04.24.2024 Page 8 of 10

#### Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

#### **Assessment:**

Toxic to aquatic life.

**Product Data:** No data available. **Substance Data:** No data available.

#### Chronic (Long-Term) Toxicity

**Assessment:** 

Toxic to aquatic life with long lasting effects.

Product Data: No data available. Substance Data: No data available.

Persistence and Degradability Product Data: No data available. Substance Data: No data available.

**Bioaccumulative Potential** 

Product Data: No data available. Substance Data: No data available.

**Mobility in Soil** 

Product Data: No data available. Substance Data: No data available. Results of PBT and vPvB assessment

**Product Data:** 

PBT assessment: This product does not contain any substances that are assessed to be a PBT. **vPvB** assessment: This product does not contain any substances that are assessed to be a vPvB.

**Substance Data:** 

PBT assessment: This product does not contain any substances that are assessed to be a PBT. **vPvB** assessment: This product does not contain any substances that are assessed to be a vPvB.

Other Adverse Effects: No data available.

#### **SECTION 13: Disposal Considerations**

# **Disposal Methods:**

It is the responsibility of the waste generator to properly characterize all waste materials according to applicable regulatory agencies. Dispose of in accordance with all applicable local, regional and national regulations.

#### Contaminated packages:

Not determined or not applicable.

#### **SECTION 14: Transport Information**

#### United States Transportation of Dangerous Goods (49 CFR DOT)

UN Number	3077
UN Proper Shipping Name	Environmentally hazardous substance, solid, n.o.s., (Maropitant citrate monohydrate)
UN Transport Hazard Class(es)	9
Packing Group	III
Environmental Hazards	Marine Pollutant (Maropitant citrate monohydrate)
Special Precautions for User	None

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

**Initial Preparation Date:** 04.24.2024 Page 9 of 10

# Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

Passenger Air/Rail	No limit
Cargo Aircraft Only	No limit
Stowage Category	A

# **International Maritime Dangerous Goods (IMDG)**

UN Number	3077
UN Proper Shipping Name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S., (Maropitant citrate monohydrate)
UN Transport Hazard Class(es)	9
Packing Group	III
Environmental Hazards	Marine Pollutant (Maropitant citrate monohydrate)
Special Precautions for User	None
EmS Number	F-A, S-F
Stowage Category	A
Excepted Quantities	E1
Limited Quantity	5 kg

# International Air Transport Association Dangerous Goods Regulations (IATA-DGR)

UN Number	3077
UN Proper Shipping Name	Environmentally hazardous substance, solid, n.o.s., (Maropitant citrate monohydrate)
UN Transport Hazard Class(es)	9
Packing Group	III
Environmental Hazards	Marine Pollutant (Maropitant citrate monohydrate)
Special Precautions for User	None
ERG Code	9L
Excepted Quantities	E1
Passenger and Cargo	400 kg
Cargo Aircraft Only	400 kg
Limited Quantity	30 Kg

# SECTION 15: Regulatory Information

# **United States Regulations**

**Inventory Listing (TSCA):** All ingredients are listed-active or exempt.

**Significant New Use Rule (TSCA Section 5):** None of the ingredients are listed.

**Export Notification under TSCA Section 12(b):** None of the ingredients are listed.

SARA Section 302 Extremely Hazardous Substances: None of the ingredients are listed.

**SARA Section 313 Toxic Chemicals:** None of the ingredients are listed.

**CERCLA:** None of the ingredients are listed.

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 04.24.2024 Page 10 of 10

Ceritant (maropitant citrate) Tablets 16mg, 24mg, 60mg, 160mg | 4s (RX)

**RCRA:** None of the ingredients are listed.

Section 112(r) of the Clean Air Act (CAA): None of the ingredients are listed.

Massachusetts Right to Know:

9004-34-6 Cellulose Listed

**New Jersey Right to Know:** 

9004-34-6 Cellulose Listed

**New York Right to Know:** None of the ingredients are listed.

Pennsylvania Right to Know:

9004-34-6 Cellulose Listed

California Proposition 65: None of the ingredients are listed.

Additional information: Not determined.

# **SECTION 16: Other Information**

# **Abbreviations and Acronyms:** None

**Disclaimer:**This product has been classified in a

This product has been classified in accordance with OSHA HCS 2012 guidelines. The information provided in this SDS is correct, to the best of our knowledge, based on information available. The information given is designed only as a guidance for safe handling, use, storage, transportation and disposal and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials, unless specified in the text. The responsibility to provide a safe workplace remains with the user.

**Initial Preparation Date:** 04.24.2024

**End of Safety Data Sheet**